Mucosis B.V. devel­oped pro­phy­lac­tic vac­cines using a nov­el adju­vant plat­form that enables a more nat­ur­al immune response as well as a broad base of pro­tec­tion.

Mucosis’s lead vac­cine can­di­date, SynGEM™, was designed to pre­vent infec­tions with Respiratory Syncytial Virus (RSV), which affect annu­aly over 60 mil­lion peo­ple world­wide. An RSV vac­cine does not yet exist.

Portfolio: MedSciences Seed Fund B.V. and MedSciences Capital II B.V.

Current prod­uct devel­op­ment stage: pro­gramme has stopped.